Dusetzina is an associate professor in the Department of Health Policy and an Ingram associate professor of cancer research at Vanderbilt. She is a health services researcher whose work focuses on measuring and evaluating population-level use and costs of medications in the United States. Dusetzina’s work has contributed to the evidence base for the role of drug costs on patient access to care and policy changes that might improve patient access to high-priced drugs.
She has been recognized for her work at a national level, including being an invited participant for two working group meetings on “Patient Access to Affordable Cancer Drugs,” hosted by the President’s Cancer Panel, and being selected to co-author a National Academies of Sciences, Engineering and Medicine report on the same topic. Dusetzina’s research has also been broadly covered by NPR, Reuters, The Washington Post, STAT News, ABC News and The Wall Street Journal.
In addition to her work on drug pricing, Dusetzina is a population health scientist and pharmacoepidemologist specializing in large data informatics. She has authored or co-authored over 85 peer reviewed applied studies using Medicaid, Medicare, and commercial insurance claims data, and contributed several methods papers to the field.
Areas of Expertise (8)
The role of drug costs on patient access to care
Population Health Research
Cancer Outcomes Research
University of North Carolina: Ph.D., Pharmaceutical Sciences 2010
University of North Carolina: Ph.D., Epidemiology 2010
University of North Carolina: B.A., Psychology 2002
Management & Society (Dual Majors)
- American Society of Health Economists
- International Society for Pharmacoepidemiology
- Society for Medical Decision Making
Selected Media Appearances (8)
Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic
Stacie Dusetzina, a health policy professor at Vanderbilt University, says that Hartung and his team looked behind the curtain to see what really happens once a generic enters a "specialty" drug market. Specialty drugs tend to be expensive, complex medications that may be difficult to administer.
"We're promised we'll spend less on managing diseases once a generic is available," Dusetzina says, adding that it hasn't played out that way. "We've been, really been, looking to generics for some price relief, and we're probably not going to get it as quickly as we want."
Brand-name drug prices rising at slower pace, lower amounts
Associated Press online
Stacie B. Dusetzina, a drug price expert and assistant professor of health policy at Vanderbilt University, thinks drugmakers may be trying to give Trump a political win by taking fewer increases and limiting them to their biggest moneymakers.
Dusetzina said some drugmakers may be making up for that by launching their new drugs at higher list prices.
“I think everybody’s just gotten caught up on how to play” the game, she said.
$2,733 To Treat Iron-Poor Blood? Iron Infusions For Anemia Under Scrutiny
There are some other, nonmedical reasons doctors might choose the more expensive drug. Newer, more expensive drugs are more likely to be heavily marketed directly to doctors, says Stacie Dusetzina, an associate professor of health policy at Vanderbilt University.
Column: Trump comes to his sense on prescription drug imports
Los Angeles Times online
"...make it difficult for Canada to subsidize our drugs,” said Stacie B. Dusetzina, an associate professor of health policy at Vanderbilt University.
The battle over who gets to sell pills for cancer treatment
And giving all the power back to cancer doctors and their pharmacies isn’t a perfect solution, either, according to Vanderbilt health policy professor Stacie Dusetzina.
“PBMs are really trying to help manage spending growth,” she said.
How Does Drug Pricing Work? Hint: It's More Like Designer Handbags Than Cars
Even if you have good insurance, says Stacie Dusetzina of Vanderbilt University, you're still paying for high drug prices indirectly.
"People tend to not really think about the premiums that they're paying for their insurance plan, which is really related to what you pay at the pharmacy counter," Dusetzina says. Your copay might be cheap, but you might be paying a lot every month for your premium.
Celebrating solutions that chip away at big problems: 3 essential reads
The Conversation online
The venture has not disclosed its business model. But “should it choose to do so, Civica Rx could theoretically set the price at or near the cost of production,” writes Stacie B. Dusetzina, a Vanderbilt University health policy and cancer scholar. That would make a big difference in a country where pharmaceuticals can sell for triple what they cost elsewhere.
Nonprofit drugmaker Civica Rx aims to cure a health care system ailmen
The Conversation online
Several years ago, drug shortages became headline news when supplies of three different drugs used to treat childhood cancers were running low in major hospitals. Sometimes shortages like those are resolved before patients are harmed. Sometimes they are not.
There are two main reasons for drug shortages that are both terrifying and becoming more frequent: There are not enough companies making these drugs and those companies aren’t producing adequate supplies. This situation has led several hospitals and foundations to form Civica Rx, a nonprofit generic drugmaker.
Selected Articles (3)
Stacie B Dusetzina, Shelley Jazowski, Ashley Cole, Joehl Nguyen
"The current Medicare Part D benefit may require greater out-of-pocket spending for beneficiaries filling prescriptions for higher-price generic drugs, compared to those filling brand-name counterparts."
Stacie B Dusetzina, Haiden A Huskamp, Nancy L Keating
"We used Medicare formulary and pricing files for the fourth quarter of 2010 through the fourth quarter of 2018 to describe point-of-sale prices (ie, excluding rebates and discounts) for a single fill of each anticancer medication. We compared prices in 2010 (or the first year a newer product was observed in the data) and 2018."
Aaron P Mitchell, Aaron N Winn, Jennifer L Lund, Stacie B Dusetzina
"Financial relationships between physicians and the pharmaceutical industry are common, but factors that may determine whether such relationships result in physician practice changes are unknown."